Skip to main content

CA224123] A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Bristoll Myers Squibb

Start Date

August 31, 2022

End Date

February 26, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Bristoll Myers Squibb

Start Date

August 31, 2022

End Date

February 26, 2027